Zevin Asset Management LLC Lowers Stake in Eli Lilly and Company $LLY

Zevin Asset Management LLC cut its stake in Eli Lilly and Company (NYSE:LLY) by 24.4% during the third quarter, HoldingsChannel reports. The fund owned 9,175 shares of the company’s stock after selling 2,956 shares during the quarter. Zevin Asset Management LLC’s holdings in Eli Lilly and Company were worth $7,001,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the stock. Laurel Wealth Advisors LLC grew its stake in Eli Lilly and Company by 78,621.2% in the second quarter. Laurel Wealth Advisors LLC now owns 11,552,336 shares of the company’s stock valued at $9,005,392,000 after purchasing an additional 11,537,661 shares during the last quarter. Norges Bank bought a new stake in shares of Eli Lilly and Company in the 2nd quarter valued at about $8,827,714,000. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and Company by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 80,407,430 shares of the company’s stock valued at $62,680,004,000 after buying an additional 1,183,038 shares in the last quarter. Franklin Resources Inc. grew its position in shares of Eli Lilly and Company by 13.4% in the 2nd quarter. Franklin Resources Inc. now owns 4,766,865 shares of the company’s stock worth $3,715,913,000 after buying an additional 564,736 shares during the last quarter. Finally, Canada Pension Plan Investment Board boosted its stake in Eli Lilly and Company by 87.2% in the second quarter. Canada Pension Plan Investment Board now owns 1,152,281 shares of the company’s stock valued at $898,238,000 after acquiring an additional 536,679 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

LLY has been the subject of several analyst reports. Daiwa Securities Group increased their price objective on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Freedom Capital raised Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 10th. Bank of America lowered their price target on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating for the company in a report on Monday, December 15th. HSBC restated a “hold” rating and set a $1,070.00 price objective on shares of Eli Lilly and Company in a report on Wednesday, December 10th. Finally, The Goldman Sachs Group set a $1,260.00 price target on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,228.54.

Eli Lilly and Company Stock Performance

NYSE LLY opened at $1,008.47 on Monday. The firm has a market capitalization of $951.35 billion, a P/E ratio of 43.94, a PEG ratio of 1.17 and a beta of 0.39. The stock has a 50-day simple moving average of $1,054.83 and a two-hundred day simple moving average of $917.84. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a fifty-two week low of $623.78 and a fifty-two week high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, February 4th. The company reported $7.54 EPS for the quarter, topping the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analyst estimates of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.Eli Lilly and Company’s revenue for the quarter was up 42.6% compared to the same quarter last year. During the same period last year, the company earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, equities analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be issued a $1.73 dividend. The ex-dividend date of this dividend is Friday, February 13th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a yield of 0.7%. Eli Lilly and Company’s dividend payout ratio is 30.15%.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Head‑to‑head trial: Novo Nordisk said its CagriSema did not meet the primary endpoint of non‑inferiority versus Lilly’s tirzepatide in an 84‑week obesity study, prompting investors to favor Lilly as the dominant player in obesity therapeutics. Novo Nordisk Stock Plunges and Eli Lilly Jumps. It’s All Down to This Weight-Loss Drug Trial.
• Positive Sentiment: Confirming coverage: Major outlets and wire services reported the trial miss broadly, accelerating market re‑rating in favor of Lilly’s obesity franchise and reducing short‑term competitive risk. Novo Nordisk’s obesity drug falls short against Eli Lilly’s in Copenhagen trial
• Positive Sentiment: Analyst upgrades/targets: Wall‑street coverage turned constructive — a published note raised Eli Lilly’s price target (reflecting stronger expected earnings from obesity products) and Erste Group flagged a positive FY2026 earnings outlook for LLY. These help underpin higher valuations. Eli Lilly and Company (NYSE:LLY) Price Target Raised to $1,050.00
• Neutral Sentiment: Institutional filing: Empirical Financial Services reported a modest increase in its Eli Lilly holdings in a prior quarter filing — a routine ownership update that adds little immediate directional pressure but signals continued institutional interest. Eli Lilly and Company $LLY Shares Acquired by Empirical Financial Services LLC d.b.a. Empirical Wealth Management

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.